



**United States** Department of Agriculture

Animal and Plant Health Inspection Service

Veterinary Services

Center for Veterinary Biologics

510 S. 17<sup>th</sup> Street, Suite 104 Ames, IA 50010 (515) 232-5785 FAX (515) 232-7120

Ms. Mary Till Legal Advisor

Commissioner for Patents

United States Patent and Trademark Office

Mail Stop Hatch-Waxman PTE

P.O. Box 1450

Alexandria, VA 22313-1450

Dear Ms. Till:

This is in regard to the application for a patent term extension of U.S. Patent No. 5,510,106 filed by the Regents of the University of California under 35 U.S.C. § 156. The veterinary biologic product claimed by the patent is Fel-O-Vax® LvK/FIV vaccine (Feline Immunodeficiency-Leukemia Virus Vaccine, Killed Virus), which was assigned VS Code No. 15D5.R0. The product is manufactured by Wyeth, through its operating subsidiary Fort Dodge Laboratories, Inc. (U.S. Veterinary License No. 112).

A review of the Center for Veterinary Biologics official records indicates that this product was subject to a regulatory period before its commercial marketing or use, as required under 35 U.S.C. § 156(a)(4).

The United States Veterinary Biological Product License was issued on June 23, 2003, which makes the submission of the patent term extension application on August 20, 2003, timely within the meaning of 35 U.S.C. § 156(d)(1).

Your understanding of the differences between this product and the product (Code 15A5.21) that was the subject of a previous patent term extension (5,275,813), as stated in your cover letter, is correct.

Should you conclude that the subject patent is eligible for patent term extension, please advise us accordingly. As required by 35 U.S.C. § 156(d)(2)(A), we will then determine the applicable regulatory review period, publish the determination in the Federal Register, and notify you of our determination.

Sincerely,

Richard E. Hill, Jr.

Director

Center for Veterinary Biologics